Business
Resverlogix : Financial Statement Q1 2026
Resverlogix : Financial Statement Q1
About this update from Resverlogix Corp.
Condensed Interim Consolidated Financial Statements For the three months ended March 31, 2026 and 2025 Notice of No Auditor Review of Unaudited Condensed Interim Consolidated Financial Statements The accompanying unaudited condensed interim consolidated financial statements of Resverlogix Corp. (the "Company") as at March 31, 2026 and for the period then ended have been prepared by and are the responsibility of the Company's management. The Company's Audit Committee and Board of Directors have reviewed and approved these unaudited condensed interim consolidated financial statements. In accordance with National Instrument 51 - 102, the Company discloses that its auditors have not reviewed the accompanying unaudited condensed interim consolidated financial statements for the periods ended March 31, 2026 and 2025. Condensed Interim Consolidated Statements of Financial Position As at: (unaudited) In thousands of US dollars Notes 2026 2025 Assets Current assets: Cash $ 50 $ 108 Prepaid expenses and deposits 143 120 Investment tax credit receivable 60 50 Other assets 46 31 Clinical supplies 435 435 Due from Zenith Capital Corp. 795 862 Total current assets 1,529 1,606 Non-current assets: Property and equipment 8 9 Intangible assets 2,708 2,589 Clinical supplies 3,744 3,744 Total non-current assets 6,460 6,342 Total assets $ 7,989 $ 7,948 Liabilities Current liabilities: Trade and other payables $ 18,654 $ 18,184 Accrued interest 5 3,375 4,622 Promissory notes payable to Zenith Capital Corp. 5 12,864 11,855 Other promissory notes 765 768 Lease liability 44 44 Warrant liability 7 (e) 424 453 Debt 8,131 8,131 Total current liabilities 44,257 44,057 Non-current liabilities: Other long-term liability 780 753 Royalty preferred shares 6 53,200 52,100 Total liabilities 98,237 96,910 Shareholders' deficiency: Share capital 7 (a) 337,109 334,931 Contributed surplus 53,922 53,936 Deficit (481,279) (477,829) Total shareholders' deficiency (90,248) (88,962) Total liabilities and shareholders' deficiency $ 7,989 $ 7,948 March 31, December 31, Going concern (note 3) Commitments and contingencies (note 9) Subsequent event (note 10) Signed on behalf of the Board: Signed: "Kenneth Zuerblis" Director Signed: "Kelly McNeill" Director Condensed Interim Consolidated Statements of Comprehensive Loss For the three months ended March 31 (unaudited) In thousands of US dollars Notes 2026...